Down-regulation of MiR-146a-5p and Its Potential Targets in Hepatocellular Carcinoma Validated by a TCGA- and GEO-based Study

Overview

Journal FEBS Open Bio

Specialty Biology

Date 2017 Apr 12

PMID 28396836

Citations 25

Authors

Xin Zhang

Zhi-Hua Ye

Hai-Wei Liang

Fang-Hui Ren

Ping Li

Yi-Wu Dang

Gang Chen

Affiliations

Soon will be listed here.

Abstract

Our previous research has demonstrated that miR-146a-5p is down-regulated in hepatocellular carcinoma (HCC) and might play a tumor-suppressive role. In this study, we sought to validate the decreased expression with a larger cohort and to explore potential molecular mechanisms. GEO and TCGA databases were used to gather miR-146a-5p expression data in HCC, which included 762 HCC and 454 noncancerous liver tissues. A meta-analysis of the GEO-based microarrays, TCGA-based RNA-seq data, and additional qRT-PCR data validated the down-regulation of miR-146a-5p in HCC and no publication bias was observed. Integrated genes were generated by overlapping miR-146a-5p-related genes from predicted and formerly reported HCC-related genes using natural language processing. The overlaps were comprehensively analyzed to discover the potential gene signatures, regulatory pathways, and networks of miR-146a-5p in HCC. A total of 251 miR-146a-5p potential target genes were predicted by bioinformatics platforms and 104 genes were considered as both HCC- and miR-146a-5p-related overlaps. RAC1 was the most connected hub gene for miR-146a-5p and four pathways with high enrichment (VEGF signaling pathway, adherens junction, toll-like receptor signaling pathway, and neurotrophin signaling pathway) were denoted for the overlapped genes. The down-regulation of miR-146a-5p in HCC has been validated with the most complete data possible. The potential gene signatures, regulatory pathways, and networks identified for miR-146a-5p in HCC could prove useful for molecular-targeted diagnostics and therapeutics.

Citing Articles

Long noncoding RNA MALAT-1: A versatile regulator in cancer progression, metastasis, immunity, and therapeutic resistance.

Xu D, Wang W, Wang D, Ding J, Zhou Y, Zhang W Noncoding RNA Res. 2024; 9(2):388-406.

PMID: 38511067 PMC: 10950606. DOI: 10.1016/j.ncrna.2024.01.015.

Serum microRNA Profiles and Pathways in Hepatitis B-Associated Hepatocellular Carcinoma: A South African Study.

Sartorius K, Sartorius B, Winkler C, Chuturgoon A, Shen T, Zhao Y Int J Mol Sci. 2024; 25(2).

PMID: 38256049 PMC: 10815595. DOI: 10.3390/ijms25020975.

The SLIT/ROBO Pathway in Liver Fibrosis and Cancer.

Basha S, Jin-Smith B, Sun C, Pi L Biomolecules. 2023; 13(5).

PMID: 37238655 PMC: 10216401. DOI: 10.3390/biom13050785.

Stress-Induced Transcriptomic Changes in Females with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Reveal Disrupted Immune Signatures.

Van Booven D, Gamer J, Joseph A, Perez M, Zarnowski O, Pandya M Int J Mol Sci. 2023; 24(3).

PMID: 36769022 PMC: 9916639. DOI: 10.3390/ijms24032698.

Cardiovascular Disease-Associated MicroRNAs as Novel Biomarkers of First-Trimester Screening for Gestational Diabetes Mellitus in the Absence of Other Pregnancy-Related Complications.

Hromadnikova I, Kotlabova K, Krofta L Int J Mol Sci. 2022; 23(18).

PMID: 36142536 PMC: 9501303. DOI: 10.3390/ijms231810635.

References

Stallings-Mann M, Waldmann J, Zhang Y, Miller E, Gauthier M, Visscher D . Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl Med. 2012; 4(142):142ra95. PMC: 3733503. DOI: 10.1126/scitranslmed.3004062. View

Chen Y, Zeng Z, Shen X, Wu Z, Dong Y, Cheng J . MicroRNA-146a-5p Negatively Regulates Pro-Inflammatory Cytokine Secretion and Cell Activation in Lipopolysaccharide Stimulated Human Hepatic Stellate Cells through Inhibition of Toll-Like Receptor 4 Signaling Pathways. Int J Mol Sci. 2016; 17(7). PMC: 4964452. DOI: 10.3390/ijms17071076. View

Zou H, Wang W, Liu Y, Braddock M, Zheng M, Huang D . Toll-like receptors in hepatocellular carcinoma: potential novel targets for pharmacological intervention. Expert Opin Ther Targets. 2016; 20(9):1127-35. DOI: 10.1517/14728222.2016.1168809. View

Cheng H, Fertig E, Ozawa H, Hatakeyama H, Howard J, Perez J . Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma. Cancer Biol Ther. 2015; 16(8):1252-8. PMC: 4623002. DOI: 10.1080/15384047.2015.1056418. View

Wilhite S, Barrett T . Strategies to explore functional genomics data sets in NCBI's GEO database. Methods Mol Biol. 2011; 802:41-53. PMC: 3341798. DOI: 10.1007/978-1-61779-400-1_3. View

Rong M, He R, Dang Y, Chen G . Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Ups J Med Sci. 2013; 119(1):19-24. PMC: 3916713. DOI: 10.3109/03009734.2013.856970. View

Wang X, El Naqa I . Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics. 2007; 24(3):325-32. DOI: 10.1093/bioinformatics/btm595. View

Andrisani O, Studach L, Merle P . Gene signatures in hepatocellular carcinoma (HCC). Semin Cancer Biol. 2010; 21(1):4-9. PMC: 3030925. DOI: 10.1016/j.semcancer.2010.09.002. View

Lau W, Lai E . Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int. 2008; 7(3):237-57. View

10.

Zhou H, Fang J, Luo X, Zhang L, Yang J, Zhang C . Downregulation of microRNA-100 enhances the ICMT-Rac1 signaling and promotes metastasis of hepatocellular carcinoma cells. Oncotarget. 2014; 5(23):12177-88. PMC: 4322964. DOI: 10.18632/oncotarget.2601. View

11.

Morgan A, Lu Z, Wang X, Cohen A, Fluck J, Ruch P . Overview of BioCreative II gene normalization. Genome Biol. 2008; 9 Suppl 2:S3. PMC: 2559987. DOI: 10.1186/gb-2008-9-s2-s3. View

12.

Smith L, Tanabe L, Ando R, Kuo C, Chung I, Hsu C . Overview of BioCreative II gene mention recognition. Genome Biol. 2008; 9 Suppl 2:S2. PMC: 2559986. DOI: 10.1186/gb-2008-9-s2-s2. View

13.

Yang J, Li M, Zheng Q . Emerging role of Toll-like receptor 4 in hepatocellular carcinoma. J Hepatocell Carcinoma. 2016; 2:11-7. PMC: 4918281. DOI: 10.2147/JHC.S44515. View

14.

Sun X, Zhang J, Hou Z, Han Q, Zhang C, Tian Z . miR-146a is directly regulated by STAT3 in human hepatocellular carcinoma cells and involved in anti-tumor immune suppression. Cell Cycle. 2015; 14(2):243-52. PMC: 4352959. DOI: 10.4161/15384101.2014.977112. View

15.

Lewis B, Shih I, Jones-Rhoades M, Bartel D, Burge C . Prediction of mammalian microRNA targets. Cell. 2003; 115(7):787-98. DOI: 10.1016/s0092-8674(03)01018-3. View

16.

Zhu K, Pan Q, Zhang X, Kong L, Fan J, Dai Z . MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. Carcinogenesis. 2013; 34(9):2071-9. DOI: 10.1093/carcin/bgt160. View

17.

Waldner M, Neurath M . Targeting the VEGF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012; 16(1):5-13. DOI: 10.1517/14728222.2011.641951. View

18.

Zhang Z, Zhang Y, Sun X, Ma X, Chen Z . microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma. Mol Cancer. 2015; 14:5. PMC: 4326400. DOI: 10.1186/1476-4598-14-5. View

19.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

20.

Zhang W, Wang H, Tong Q, Jie S, Yang D, Peng C . Involvement of TLR2-MyD88 in abnormal expression of miR-146a in peripheral blood monocytes of patients with chronic hepatitis C. J Huazhong Univ Sci Technolog Med Sci. 2015; 35(2):219-224. DOI: 10.1007/s11596-015-1414-5. View